Hospital
Pascack Valley Hospital LLC
Pascack Valley Hospital LLC was paid $7.02M by Medicaid between Jan 2018 and Nov 2024, across 91 billing codes. Its largest line is 99285, emergency room visit (most serious) — 34% of everything it billed.
33Billing provider infoPASCACK VALLEY HOSPITAL LLC
WESTWOOD, NJ 07675
WESTWOOD, NJ 07675
33aNPI1205176062assigned 02/15/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.02M
24GClaims112,573
24DCodes billed91
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in New Jersey
Rank by total paid#64 of 93
Median peer was paid$30.60M
This provider vs. median0.2×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 10,038 | $709K | |
| 2019 | 12,258 | $927K | |
| 2020 | 10,961 | $761K | |
| 2021 | 14,455 | $1.08M | |
| 2022 | 19,319 | $1.27M | |
| 2023 | 26,290 | $1.21M | |
| 2024incomplete | 19,252 | $1.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 34% | 5,144 | 4,446 | $2.37M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 28% | 5,651 | 4,977 | $1.99M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 4,285 | 3,847 | $1.02M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.1% | 1,073 | 928 | $287K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 1,602 | 1,368 | $105K |
| OP370 | 1.4% | 535 | 424 | $101K | |
| OP710 | 1.4% | 543 | 430 | $101K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 2,519 | 2,163 | $90K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.3% | 1,463 | 1,154 | $90K |
| G0378 | Hospital observation service, per hour | 1.3% | 106 | 91 | $90K |
| 80053 | Comprehensive metabolic panel | 1.1% | 7,745 | 6,310 | $78K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 2,020 | 1,652 | $72K |
79 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,249 | $58K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,184 | $57K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,758 | $57K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 301 | $46K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 8,502 | $42K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 450 | $29K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 590 | $24K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,458 | $22K |
| OP250 | <1% | 15,890 | $21K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 740 | $20K |
| 86900 | <1% | 1,193 | $17K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 107 | $17K |
| 59025 | Fetal non-stress test | <1% | 91 | $16K |
| 81001 | <1% | 4,226 | $15K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,994 | $15K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 780 | $14K |
| OP272 | <1% | 651 | $14K | |
| 84484 | <1% | 2,132 | $11K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,012 | $10K |
| 86850 | <1% | 1,057 | $8K | |
| 83735 | <1% | 1,649 | $8K | |
| 81025 | <1% | 2,149 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 108 | $7K |
| 83690 | <1% | 2,254 | $7K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 65 | $6K |
| 87088 | <1% | 1,458 | $6K | |
| 86901 | <1% | 1,207 | $5K | |
| 87428 | <1% | 258 | $5K | |
| 85610 | <1% | 1,168 | $5K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 568 | $5K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 440 | $4K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 2,945 | $4K |
| 82962 | <1% | 230 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 204 | $3K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 50 | $3K |
| 0012A | <1% | 101 | $3K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 33 | $3K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 774 | $3K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 45 | $2K |
| 0011A | <1% | 93 | $2K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 49 | $2K |
| 76820 | <1% | 45 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 157 | $2K |
| 87071 | <1% | 233 | $2K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 28 | $2K |
| 84703 | <1% | 478 | $1K | |
| 82948 | <1% | 214 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,670 | $1K |
| J2704 | Injection, propofol, 10 mg | <1% | 371 | $1K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 932 | $920.54 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 68 | $877.58 |
| 36416 | <1% | 126 | $707.29 | |
| 83605 | <1% | 163 | $699.30 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 176 | $673.47 |
| 85379 | <1% | 160 | $649.21 | |
| 87040 | <1% | 65 | $582.58 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 99 | $543.55 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 618 | $493.31 |
| 73564 | <1% | 23 | $488.02 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,345 | $482.25 |
| 85730 | <1% | 100 | $458.13 | |
| 83880 | <1% | 38 | $445.25 | |
| 84702 | <1% | 45 | $311.65 | |
| OP258 | <1% | 209 | $300.68 | |
| OP270 | <1% | 149 | $267.57 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 540 | $259.70 |
| 87070 | <1% | 55 | $197.02 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 139 | $128.70 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 74 | $81.69 |
| 87807 | <1% | 58 | $81.16 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 31 | $71.52 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 93 | $53.51 |
| OP255 | <1% | 14 | $47.11 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 28 | $41.54 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 26 | $38.32 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 59 | $21.57 |
| J3490 | Unclassified drugs | <1% | 12 | $16.19 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 13 | $6.86 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 20 | $2.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHOLLIMAN, EMILY (CEO)